

## Toward Quality Assurance for Metaphase FISH: A Multicenter Experience

Gordon W. Dewald, Richard Stallard, Patricia I. Bader, Kathy Chen, Julie Zenger-Hain, Catherine J. Harris, Rodney Higgins, Betsy Hirsch, Wei-Tong Hsu, Eric Johnson, Virginia Kubic, T.W. Kurczynski, James M. Malone, D. James McCorquodale, Karen Meilinger, Lorraine F. Meisner, J.W. Moore, Stuart Schwartz, Steven Siembieda, Patrick D. Storto, Gail Vance, Peter Van Tuinen, Ann Wiktor, and Jar-Fee Yung

Mayo Clinic and Mayo Foundation, Rochester, Minnesota (G.W.D.); Great Lakes Regional Genetics Group (R.S.), University of Wisconsin (E.J., L.F.M.), Madison; Fort Wayne Regional Laboratories, Fort Wayne, Indiana (P.I.B.); Lutheran General Hospital, Park Ridge, Illinois (K.C.); Oakwood Hospital, Dearborn, Michigan (J.Z.-H.); Cook County Hospital, Chicago, Illinois (C.J.H.); Abbott Northwestern Hospital, Minneapolis, Minnesota (R.H.); University of Minnesota Hospitals and Clinics, Minneapolis (B.H.); Rush Presbyterian–St. Luke's Medical Center, Chicago, Illinois (W.-T.H.); Hennepin County Medical Center, Minneapolis, Minnesota (V.K.); Medical College of Ohio, Toledo (T.W.K.); Children's Hospital Medical Center, Akron, Ohio (J.M.M.); Michael Reese Hospital, Chicago, Illinois (D.J.M.); Butterworth Hospital, Grand Rapids, Michigan (K.M.); Children's Hospital, Columbus, Ohio (J.W.M.); University Hospitals, Cleveland, Ohio (S.Sc.); St. Paul Ramsey Medical Center, St. Paul, Minnesota (S.Si.); Michigan State University, East Lansing (P.D.S.); Indiana University, Indianapolis (G.V.); Medical College of Wisconsin, Milwaukee (P.V.T.); Henry Ford Hospital, Detroit, Michigan (A.W.); and Mercy Hospital and Medical Center, Chicago, Illinois (J.-F.Y.)

Although fluorescent *in situ* hybridization (FISH) is rapidly becoming a part of clinical cytogenetics, no organization sponsors multicenter determinations of the efficacy of probes. We report on 23 laboratories that volunteered to provide slides and to use a probe for small nuclear ribonucleoprotein polypeptide N (SNRPN) and a control locus. Experiences with FISH for these laboratories during 1994 ranged from 0 to 645 utilizations (median = 84) involving blood, amniotic fluid, and bone marrow. In an initial study of hybridization efficiency, the median percentage of metaphases from normal individuals showing two SNRPN and two control signals for slides prepared at each site was 97.0 (range = 74–100); for slides prepared by a central laboratory, it was 97.8 (range = 81.6–100). In a subsequent blind study, each laboratory attempted to score 5 metaphases from each of 23 specimens [8 with del(15)(q11.2→q12) and 15 with normal #15 chromosomes]. Of 529 challenges, the correct SNRPN pattern was found in 5 of 5 metaphases in 457 (86%) and in 4 of 5 in 33 (6%). Ambiguous, incomplete, or no results were reported for 32 (6%) challenges. Seven

(1%) diagnostic errors were made, including 6 false positives and 1 false negative: 1 laboratory made 3 errors, 1 made 2, and 2 made 1 each. Most errors and inconsistencies seemed due to inexperience with FISH. The working time to process and analyze slides singly averaged 49.5 min; slides processed in batches of 4 and analyzed singly required 36.9 min. We conclude that proficiency testing for FISH by using an extensive array of challenges is possible and that multiple centers can collaborate to test probes and to evaluate costs. © 1996 Wiley-Liss, Inc.

**KEY WORDS:** mosaicism, proficiency testing, Prader–Willi syndrome, SNRPN probe, metaphase FISH, quality assurance, hybridization efficiency, workload

### INTRODUCTION

Fluorescence *in situ* hybridization (FISH) is rapidly becoming part of clinical practice in cytogenetics. Fluorescent DNA probes are available as chromosome-specific paints (CSP), for chromosome-specific alpha satellites (alphoids), and for certain locus-specific sites (cosmids). FISH is used to examine cells in interphase and metaphase and can be applied to almost any type of tissue [Trask, 1991]. However, the reproducibility, normal range, and accuracy of FISH in clinical practice have been established for only a few probes [Jenkins

Received for publication August 2, 1995; revision received November 1, 1995.

Address reprint requests to Gordon Dewald, Ph.D., Cytogenetics Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

et al., 1992; Kibbelaar et al., 1993; Dewald et al., 1993a, 1993b; Lu et al., 1994; Schad and Dewald, 1995]. Moreover, no probe for the nascent technology has been approved for diagnostic services by the Food and Drug Administration.

We are not aware of any group being organized to collect data from the same subjects to validate probes for FISH, to measure the effort (workload) associated with FISH, to test the efficacy of FISH in clinical service, or to assess the accuracy of laboratories through proficiency testing. We organized 23 cytogenetic laboratories in the Great Lakes Regional Genetics Group (GLaRGG) to test the possibility of accomplishing all of these goals. We report on a project involving laboratories that volunteered to provide slides and to use FISH with DNA probes for the small nuclear ribonucleoprotein polypeptide N (SNRPN) site in 15q11→13 [Ozcelik et al., 1992] and a control locus in 15q22 for the PML gene.

## METHODS AND MATERIALS

### Participants

Fifty-nine institutions providing clinical cytogenetic services within the states covered by GLaRGG (Illinois, Indiana, Michigan, Minnesota, Ohio, and Wisconsin) were contacted by letter about participating in a possible project with FISH. Thirty-three laboratories responded, and 23 agreed to provide slides and to dedicate personnel for participation. Although self-selected, the participants represented a reasonable sample of cytogenetic laboratories in the United States.

### Equipment, Experience, and Organization

By questionnaire, participants were asked about filters, light sources, wattages, brands, and models of the microscopes used for FISH. From this information, Oncor, Inc. provided each participant with reagents and probes from a single lot for detection with fluoroisothiocyanate (FITC) and propidium iodide (PI), with rhodamine and 4'-6'-diamidino-2-phenylindole dihydrochloride (DAPI), or with FITC and DAPI. Each participant was also asked about the number of times CSP and alphoid and cosmid probes were used in 1994 for clinical evaluations of peripheral blood, amniotic fluid, and bone marrow. Each application of a probe to a sample was counted as a separate utilization.

A general plan describing the course of the project was supplied to each participant. On specific dates, laboratories prepared slides and shipped them synchronously to one of the authors (R.S.) by overnight delivery. R.S. returned a set of coded slides to each participant by overnight delivery so that the age of the slides could be kept approximately constant for all sites. Special forms and instructions were created before each step of the project and were shipped to the participants at the appropriate times to help assure that data were collected and recorded uniformly. Results were summarized and distributed to participants so that each could know its own results and could compare them anonymously with those of other participants.

The cosmid probe for the SNRPN site was chosen because of its common utilization for studying chromosomes of patients with the Prader-Willi syndrome. The probe detects microscopic and submicroscopic deletions in 15q11.2→q12 [Ozcelik et al., 1992], but it does not detect genic or uniparental disomic causes of the syndrome.

### Hybridization Efficiency

Hybridization efficiency of a probe in a FISH study is defined as the percentage of scorable metaphases, with a number of fluorescent signals matching the cytogenetic standard. The hybridization efficiency of SNRPN in each laboratory was established with slides prepared by the participants themselves and with slides prepared by a central laboratory. Participants prepared a single slide by using lymphocytes from a chromosomally normal individual. That slide and a partial karyotype of the #15 chromosomes were then shipped to R.S. At the same time, a central laboratory prepared 23 slides by using lymphocytes from a chromosomally normal individual and sent these and a partial karyotype of the #15 chromosomes to R.S. The slides prepared by each laboratory was labeled A, and the slides from the central laboratory were labeled B. Each A slide was then returned to the laboratory that made it, along with a B slide.

Each participant was to examine the A and B slides in the same way to collect 50 consecutive metaphases meeting the manufacturer's criteria for scoring SNRPN signals, i.e., only metaphases with 2 control signals could be scored. Participants were to record the number of scorable metaphases with 0, 1, 2 or >2 SNRPN signals. If participants were unable to score 50 metaphases showing 2 control signals, they were to examine and record as many scorable metaphases as possible. In addition, participants were to count the number of metaphases with 0, 1, or ≥3 control signals encountered while examining each slide. These metaphases, which did not meet the scoring criteria, were used to calculate the percentage of unacceptable metaphases. Results were recorded and returned for coding within 1 week.

### Blind Study

Once studies of hybridization efficiency were completed, each participant provided slides with metaphases from the leukocytes of either a chromosomally normal individual or one known to have a nonmosaic del(15)(q11.2→q12) and the Prader-Willi syndrome. Each laboratory prepared a set of 23 unlabeled slides and sent them and a partial karyotype of the #15 chromosomes to R.S. These slides were coded, and each laboratory was shipped a set of the 23 types of specimens to study blindly with the SNRPN probe. Participants attempted to collect 5 consecutive metaphases from each slide showing 2 control signals and to record the number of these metaphases with 0, 1, 2, or >2 SNRPN signals. While selecting the 5 scorable metaphases, participants also recorded the number of metaphases with 0, 1, or ≥3 control signals. The results were returned to R.S. within 2 weeks for analysis.

### Workload Recording

The form for recording information about the workload associated with FISH followed the manufacturer's instructions for using the SNRPN probe, but the form was not a substitute for those instructions. Twenty-seven steps were delineated for timing. To give each site some preliminary experience before the actual timings, participants processed the slides in numerical order, beginning with slide 1 and working through to slide 23. Timings to measure work in minutes and seconds were taken for slides 13 and 14, processed singly, and for slides 15–18 and 19–22, processed in batches of 4. Participants provided timings for only successful hybridizations but reported any rehybridizations required for slides 13 and 14.

## RESULTS

### Equipment

Nine laboratories used Zeiss microscopes, 7 used Olympus, 4 used Lietz, and 3 used Nikon. Nineteen laboratories used 100-W mercury light sources, 3 used 50-W mercury light sources, and 1 used both. Nineteen laboratories used the FITC/PI system for detecting fluorescence, 3 used rhodamine/DAPI, and 1 used FITC/DAPI.

### Experience With FISH

The total number of utilizations of probes with FISH for the 23 laboratories during 1994 was 2,974. The me-

dian number of utilizations was 84 but ranged from 0 to 645 (Fig. 1). Of the utilizations, 1,708 (57%) employed cosmids, 963 (32%) alphoids, and 303 (10%) CSPs. Of the utilizations, 1,647 (55%) involved peripheral blood, 750 (25%) amniotic fluid, and 577 (19%) bone marrow. FISH was used by 22 laboratories on peripheral blood, by 17 on amniotic fluid, and by 17 on bone marrow (Table I). Only 1 laboratory did not use FISH for evaluations in 1994.

### Hybridization Efficiency

Upon review by R.S., none of the 23 partial karyotypes supplied by the participants for the #15 chromosomes on the A slides suggested a visible deletion in 15q11.2→q12. The partial karyotype supplied by a central laboratory for the #15 chromosomes on the B slides also did not suggest a deletion in 15q11.2→q12.

One laboratory could not perform the initial hybridizations of the A or B slides, and another laboratory only processed slide B. Seventeen of 21 laboratories found 50 metaphases on the A slides, and 13 of 22 laboratories found 50 metaphases on the B slides. The 4 laboratories finding fewer than 50 metaphases on the A slides found 15, 43, 45, and 45 metaphases. The 9 laboratories finding fewer than 50 metaphases on the B slides found 13, 16, 37, 38, 39, 40, 43, 45, and 47 metaphases. No laboratory reported any problem with the slides.

Overall, participants examined 1,082 metaphases from the A slides and rejected 134 (12.4%) as unsuit-




Fig. 1. Experience of each participating laboratory in the 1994 FISH study.

TABLE I. Experience of Participants With FISH by Tissue Type

Number of utilizations	Number of laboratories <sup>a</sup>		
	PB	AF	BM
0	1	6	6
1-20	6	10	10
21-50	6	2	5
51-100	5	1	1
101-300	3	4	0
301-650	2	0	1

<sup>a</sup>PB = peripheral blood; AF = amniotic fluid; BM = bone marrow.

able for scoring. Participants examined a total of 1,012 metaphases from the B slides and considered 94 (9.3%) unsuitable for scoring. For the A slides, the median percentage of unsuitable metaphases was 7.4 (range = 0-59.5%). For the B slides, the median percentage of unsuitable metaphases was 8.7 (range = 0-27.5%).

The hybridization efficiency was calculated for the A and B slides by finding the mean percentage of all scorable metaphases with 2 SNRPN signals (Table II). For the A slides, the median hybridization efficiency was 97.0 (range = 74-100%) for 21 participants studying metaphases from 21 different patients. For the B slides, the median hybridization efficiency was 97.8 (range = 81.6-100%) for 22 participants studying metaphases from a single patient.

### Blind Study

Seven distinctive styles of slides were submitted by the 23 participants. Four styles were unique to single participants. The 3 other styles were used by 7, 7, and 5 participants. Thus, in the blind study, only 4 participants could have recognized their own single submissions in the set of 23 slides each examined.

By conventional cytogenetic studies and by review of a partial karyotype from each of the #15 homologous pairs, 8 of the specimens were known to have a del(15)(q11.2→q12) and 15 were known to have normal #15 chromosomes. In the blind study, the 23 participants attempted to score 5 metaphases from each of the 23 specimens for the presence or absence of SNRPN sites. Thus, as a group, the participants had a total of 529 challenges (23 participants × 23 challenges).

Participants examined 3,466 metaphases in the blind study. This total excludes the results from 1 laboratory that did not record "unacceptable" metaphases for any challenge and from single slides evaluated subjectively by 2 other laboratories. Of the metaphases, 2,116 were

observed on slides showing normal #15 chromosomes, and 1,350 were observed on slides showing del(15)(q11.2→q12). Participants rejected 15.7% (median) of metaphases (range = 0-79 metaphases) examined on slides with normal metaphases and 33.9% (median) of metaphases (range = 0-111 metaphases) on slides with abnormal metaphases. The percentage of observations of single SNRPN signals on slides with normal metaphases and the percentage of observations of 2 SNRPN signals on slides with abnormal metaphases were both 3.3.

Of the 529 possible challenges, the correct SNRPN pattern was found in 5 of 5 metaphases in 457 (86.4%) and in 4 of 5 metaphases in 33 (6.2%) (Table III). For 32 (6.0%) of the challenges, results were unreliable (2 metaphases with 1 SNRPN signal and 3 with 2 signals or 3 metaphases with 1 SNRPN signal and 2 with 2 signals), incomplete (0-4 metaphases, but at least some metaphases were examined), or no data (2 due to broken slides and 6 to no metaphases observed). The number of participants finding 5 metaphases in 23, 22, 21, 20, 19, 18, 14, 12, and 10 of the challenges was 6, 6, 3, 2, 2, 1, 1, 1, and 1, respectively.

Seven diagnostic errors, including 6 false positives and 1 false negative, were reported. Thus, the overall percentage of diagnostic errors was 1.3 (7/529). Four participants made 1, 1, 2, and 3 diagnostic errors. These participants utilized FISH 210, 70, 7, and 15 times, respectively, in 1994. For the same period, the 2 participants reporting the greatest numbers of results with unreliable, incomplete, or no data (9/23 and 7/23) utilized FISH 70 and 237 times, respectively. The participants agreed that the pattern of SNRPN signals matched the cytogenetic standard for each of the 23 specimens in no fewer than 17 of 23 examinations of metaphases from the same specimen. The correct pattern of fluorescence was reported for ≥18 of 23 challenges by 20 participants and for ≤14 of 23 challenges by 3 participants. None of the 23 types of specimens presented a consistent problem for participants.

### Workload Recording

Each participant provided data from recording workload for slides processed one at a time and for slides processed in batches of 4 (Table IV). Some laboratories did not time all steps, and some laboratories provided internally inconsistent timings. We used only data from the laboratories providing complete, internally consistent timings for the present report.

For 11 laboratories, the time to process one slide at a time averaged 19.9 min. When slides were processed in batches of 4 by 9 laboratories, the average time required per slide was 8.3 min. It took 11 laboratories on average 27.5 min to score 5 metaphases and to capture 2 documentary images. None of these 11 laboratories rehybridized either of the 2 slides processed singly. On average, it took 10 laboratories another 1.1 min to prepare solutions for each slide.

## DISCUSSION

### Organization

This project was designed to simulate FISH studies with SNRPN in clinical practice, beginning with pre-

TABLE II. Percentages of Metaphases Scored for SNRPN Signals on A and B Slides

Signals	A slides (21 patients)			B slides (22 slides, 1 patient)		
	Median	Max	Min	Median	Max	Min
0	0.0	10.0	0.0	0.0	4.0	0.0
1	2.0	11.1	0.0	2.0	15.8	0.0
2	97.0	100.0	74.0	97.8	100.0	81.6
>2	0.0	6.0	0.0	0.0	4.0	0.0

TABLE III. Results of Blind Study Showing Normal and Abnormal Specimens Ordered Left to Right in Decreasing Levels of Consensus Based on 5 of 5 Metaphases

	Specimen number <sup>a</sup>																								
	Chromosomally normal																	del(15)(q11.2→q12)							
	21	2	4	12	20	22	22	21	7	14	16	11	18	23	1	3	19	9	10	13	15	17	5	6	8
Metaphases	23	22	22	22	22	22	21	21	21	21	21	20	19	19	18	18	18	20	20	19	19	19	18	17	17
5 Normal																									
5 Abnormal																									
4 Normal,																									
1 abnormal																									
4 Abnormal,																									
1 normal																									
Unreliable																									
results																									
0-4																									
No data																									

<sup>a</sup>Specimen number corresponds to the number assigned each participant in Figure 1. Boxes indicate diagnostic errors.

pared slides and ending with the completion of analyses at the microscope (including capturing 2 documentary images of metaphases). The manufacturer's instructions for using the SNRPN probe proved functional. Some laboratories asked to tailor procedures to their own experiences. We discouraged deviations from the manufacturer's instructions to assure comparable data, especially data from the segment involving the recording of workload.

The project required each laboratory to complete the study to determine hybridization efficiency in 2 days and the blind study in 2 weeks. Requiring processing of slides from 23 specimens in a short time may have contributed to the outcomes for some participants. None, however, withdrew from the project when the exact calendar became available. All requests for accommodating the needs of specific participants were met within the framework of the project, which ensured similar freshness for all slides and a timely return of data.

### Hybridization Efficiency

The initial work in each laboratory provided all participants the opportunity to become familiar with a specific lot of the SNRPN probe and to review the manufacturer's instructions for utilization and scoring. Participants examined normal metaphases on both slides they had prepared themselves (A) and on slides prepared by a central laboratory (B). Overall, there was no notable difference between the numbers of metaphases scored or the percentages of metaphases rejected from the A (21 different subjects) and B (22 trials, 1 subject) slides. The median hybridization efficiency and the median percentage of metaphases with unexpected patterns of signal on the A and B slides were also without notable difference (Table II). Moreover, the low and indistinguishable percentages of metaphases on the A and B slides with only 1 SNRPN signal and the high and indistinguishable hybridization efficiencies derived from the A and B slides documented the reliability of the lot of probe.

### Blind Study

Participants rejected similar proportions of the metaphases examined while attempting to score 50 metaphases on the A and B slides for determining hybridization efficiency (median = 7.4% and 8.7%, respectively). Participants in the blind study rejected larger proportions of the metaphases examined while attempting to score just 5 metaphases from either the 8 slides with a del(15)(q11.2→q12) or from the 15 with normal #15 chromosomes (median = 33.9 and 15.7%, respectively). Apparently, under the 2 sets of similar conditions, technologists applied different criteria for scoring metaphases. This should be considered for FISH when developing and applying policies for becoming familiar with probes, for examining clinical samples, and for recording workload.

There was no consistent problem with any of the 23 types of specimens provided by the participants (Table III). Participants reached a level of consensus  $\geq 73.9\%$  for the pattern of SNRPN signals in each of the 23 specimens. A pattern of SNRPN signals matching the cyto-

TABLE IV. Summary of Workload From 27 Timed Steps\*

Steps	Labs	Mean	SD	Min	Max
Processing single slides					
Initial preparation	11	6:42	4:15	1:00	13:18
Hybridize	11	7:24	4:05	2:56	14:33
Posthybridization	11	3:27	2:38	1:33	10:24
Detection	11	2:22	0:54	1:10	3:37
Total	11	19:55	11:53	6:39	41:52
Processing batched slides					
Initial preparation	9	2:15	1:05	1:05	4:18
Hybridize	9	2:58	1:22	1:27	5:37
Posthybridization	9	1:22	0:53	0:45	2:54
Detection	9	1:42	0:48	0:45	3:22
Total	9	8:17	3:42	4:46	16:09
Analysis and documentation	11	27:29	16:35	5:37	55:20
Solution preparation	10	1:07	0:36	0:11	2:11

\*Results expressed in minutes:seconds per slide.

genetic standard was detected in 5 of 5 or 4 of 5 metaphases in 92.6% of the 529 challenges. A pattern of fluorescence matching the cytogenetic standard was found in  $\geq 18$  of 23 challenges by 20 laboratories and in  $\leq 14$  of 23 by 3. Participants reported inconsistent, incomplete, or no data for only 6.0% of the challenges, but half of such errors were made by just 2 of the 23 participants. Diagnostic errors were reported for 1.3% of the challenges, but the 7 errors were made by only 4 participants. Thus, the blind study identified laboratories needing improvement.

There was no apparent relation between performance in the blind study and the type of microscope or system for detection of fluorescence used by participants. In general, however, participants reporting less total experience with FISH seemed more likely to make diagnostic and other errors in the blind study.

### Workload Recording

Variation was evident in the complete and internally consistent sets of data from timings of the effort required for FISH (Table IV). Some of the apparent variation may have been due to inexperience with workload recording, inaccurate timings, and incomplete directions for timing. Nevertheless, we believe that the remaining interlaboratory variations are real and do reflect different levels of efficiency.

From recording workload, processing slides one at a time required approximately 20 min, but processing 4 at a time only required about 8 min per slide. The time for analysis at the microscope, including capturing 2 documentary images per slide, averaged 27.5 min. Preparing solutions specifically for FISH consumed an additional 1.1 min for each specimen. With this information, it is possible to calculate an average cost of labor associated with SNRPN and to estimate the number of technologists needed for studies with SNRPN.

### Mosaicism in Prader-Willi Syndrome

The number of metaphases that need to be examined by FISH for clinical practice has not been established.

The results of this project suggest that examining 5 metaphases with FISH for deletions may suffice when coupled with standard cytogenetics. However, if mosaicism were suspected from clinical observations, conventional cytogenetics, or metaphases with unexpected numbers of SNRPN signals, it would be important to examine more metaphases [Mowery-Rushton et al., 1994]. The number of additional metaphases could be determined statistically, depending on the degree of confidence required, on the level of mosaicism to be excluded and on the efficiency of hybridization of the probe.

A single SNRPN signal appeared in 3.3% (54/1,617) of metaphases from the 15 patients with cytogenetically normal #15 chromosomes. A single SNRPN signal also appeared in 3.4% (32/948) of metaphases collected from the A slides (21 different chromosomally normal patients) and in 3.2% (29/918) collected from the B slides (22 trials from 1 chromosomally normal patient) while determining hybridization efficiency of the SNRPN probe. We believe all these unexpected patterns of signals are artifacts of the testing system and are not indicative of mosaicism. Similarly, the 3.3% (27/821) of metaphases from the 8 patients with cytogenetically evident, nonmosaic del(15)(q11.2→q12) chromosomes showing 2 SNRPN signals are probably artifacts of the testing system. These observations suggest that detection of cell lines occurring at frequencies approaching 100% minus the hybridization efficiency (e.g., 3% for SNRPN) would be difficult to document. More examinations of metaphases from the same patients by multiple centers with extensive experience are needed to evaluate the problem of detecting mosaicism with FISH.

### Future Direction

Results from the initial hybridization study showed no notable difference between slides prepared by individual laboratories and those prepared by a central laboratory. In the blind study, each of the 23 types of specimens was prepared by a different participant. Nevertheless, consensus was reached on all types of

specimens at a level of  $\geq 17$  of 23, and participants experienced no consistent problem with any of the 23 types of specimens. Plainly, 1 or more laboratories could contribute slides to proficiency tests for FISH. This finding demonstrates the ease with which the pool of clinical challenges could be expanded for proficiency testing, clinical trials, and evaluating guidelines for FISH.

The results from determining hybridization efficiency of the SNRPN probe and from the blind study were summarized and distributed so that each participant could compare its result anonymously with those of other participants. This system of reporting is similar to the CAP/ACMG proficiency test for standard cytogenetics, which has proved to be an excellent mechanism for improving laboratories [Hoeltge et al., 1993]. The CAP/ACMG proficiency test for standard cytogenetics expects that 80% of participants will report the same answer before a challenge is considered satisfactory. Because 87% of the challenges in the blind study were answered completely and in accord with the cytogenetic standard, our multicenter trial with molecular cytogenetics is comparable to the CAP/ACMG system. Further comparative and interlaboratory testing would help validate probes and improve both the experience and confidence of participants.

This study was not designed to establish the specificity and sensitivity of the SNRPN probe, although such calculations could be made from the data in Table II. Nevertheless, we believe this initial work clearly demonstrates the feasibility of conducting a definitive study of the characteristics of SNRPN and other probes in multiple clinical laboratories by using standardized instructions for application of a probe and uniform criteria for scoring fluorescent signals. Moreover, this project demonstrates that proficiency testing of FISH with an extensive array of challenges is possible and that multiple centers can collect data to evaluate workload. We believe this system, or a similar one, would improve the quality, efficiency, and utility of FISH in clinical practice, just as proficiency testing has improved standard clinical cytogenetics.

## ACKNOWLEDGMENTS

This study was supported in part by project MCJ-551004-04 from the Maternal and Child Health Bureau (Title V Social Security Act), Health Resources and Services Administration, Department of Health and Human Services and in part by Oncor, Inc. (Gaithersburg, MD), which donated the DNA probe sets.

## REFERENCES

- Dewald GW, Schad CR, Christensen ER, Tiede AL, Zinsmeister AR, Spurbeck JL, Thibodeau S, Jalal SM (1993a): The application of fluorescent in situ hybridization to detect *Mbc/abl* fusion in variant Ph chromosomes in CML and ALL. *Cancer Genet Cytogenet* 71:7-14.
- Dewald GW, Schad CR, Christensen ER, Law ME, Zinsmeister AR, Stalboerger PG, Jalal SM, Ash RC, Jenkins RB (1993b): Fluorescent in situ hybridization with X and Y chromosome probes for cytogenetic study on bone marrow cells after opposite sex transplantation. *BMT* 12:149-154.
- Hoeltge GA, Dewald GW, Palmer CG, David-Nelson MA, Saikovich I, Patil S, Schwartz S, Schneider NR, Herrmann M (1993): Proficiency testing in clinical cytogenetics: A 6-year experience with photographs, fixed cells, and fresh blood. *Arch Pathol Lab Med* 117:776-779.
- Jenkins RB, Le Beau MM, Kraker WS, Borell TJ, Stalboerger PG, Davis EM, Penland L, Fernald A, Espinosa R, Schaid DJ, Noel P, Dewald GW (1992): Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens. *Blood* 79:3307-3315.
- Kibbelaar RE, Mulder JSR, Dreef EJ, van Kamp H, Fibbe WE, Wessels JW, Beverstock GC, Haak HL, Kluin PhM (1993): Detection of monosomy 7 and trisomy 8 in myeloid neoplasia: a comparison of banding and fluorescence in situ hybridization. *Blood* 82:904-913.
- Lu PY, Hammitt DG, Zinsmeister AR, Dewald GW (1994): Dual color fluorescence in situ hybridization to investigate aneuploidy in sperm from 33 normal males and a man with a t(2;4;8) (q23;q27; p21). *Fertil Steril* 62:394-399.
- Mowery-Rushton PA, Hanehett JM, Surti U (1994): Identification of Prader-Willi syndrome mosaicism by fluorescent in situ hybridization [Abstract 640]. *Am J Hum Genet* 55:A113.
- Ozcelik T, Leff S, Robinson W, Donlon T, Lalande M, Sanjines E, Schinzel A, Francke U (1992): Small nuclear ribonucleoprotein polypeptide N (SNRPN), an expressed gene in the Prader-Willi syndrome critical region. *Nature Genet* 2:265-269.
- Schad CR, Dewald GW (1995): Building a new clinical test for fluorescence in situ hybridization. *Appl Cytogenet* 21:1-4.
- Trask B (1991): Fluorescence in situ hybridization: Applications in cytogenetics and gene mapping. *Tech Focus* 7:149-154.